Comparison of 12-chloroscoulerine enantiomers on animal behavior to dopamine receptors

AIM

To compare the pharmacological characteristics of 12-chloroscoulerine (CSL) enantiomers to dopamine (DA) receptors.

METHODS

Radioligand receptor binding assay with calf striatum and behavioral tests of mice or rats were used.

RESULTS

In the competitive binding assay, the affinities (Ki) of l-CSL to D1 and D2 receptors were 5.7 nmol.L-1, while those of d-CSL for D1 and D2 receptors were 135 and 9150 nmol.L-1, respectively. The Ki of dl-CSL to D1 and D2 receptors were 8.9 and 9.6 nmol.L-1, respectively, which were slightly weaker than that of l-CSL. In the behavioral experiments, CSL enantiomers 5-60 mg.kg-1 antagonized the stereotypy induced by apomorphine in rats, and 5-150 mg.kg-1 produced catalepsy. The enantiomers 10-60 mg.kg-1 reduced the mice jumping behavior induced by amphetamine + levodopa. l-CSL 10-80 mg.kg-1 antagonized the spontaneous locomotor activity of normal or amphetamine-treated mice.

CONCLUSION

CSL enantiomers are antagonists to DA receptors: l-CSL > dl-CSL >> d-CSL.

Supraspinal D2 receptor involved in antinociception induced by l-tetrahydropalmatine

AIM

To study the role of dopamine (DA) receptors in l-tetrahydropalmatine (l-THP)-induced antinociception.

METHODS

The intraperitoneal (i.p.) and intrathecal (ith) injections were used to give the drugs. The tail-flick test was used to assess the nociceptive threshold of rats.

RESULTS

By i.p. injection, l-THP (10, 20, 40 mg.kg-1) as well as D2 receptor antagonist spiperone (1, 2, 3 mg.kg-1) produced dose-dependent antinociceptive effects on the nociception of rats, while D2 receptor agonist quinpirole, D1 receptor agonist SKF38393, and D1 receptor antagonist Sch-23390 showed no antinociception. Moreover, l-THP- or spiperone-induced antinociception was markedly attenuated by quinpirole (2, 3 mg.kg-1) but not SKF38393 or naloxone. On the other hand, ith quinpirole (20, 30, 40 micrograms.kg-1) also induced a dose-dependent antinociception, while ith l-THP, spiperone, SKF38393, and Sch-23390 did not exhibit any antinociception. Furthermore, ith spiperone (20, 30, 40 micrograms.kg-1) but not Sch-23390 dose-dependently antagonised the antinociception induced by quinpirole. l-THP (ith, 100, 200, 300 micrograms.kg-1) also dramatically attenuated the quinpirole-induced antinociception with a dose-dependent relationship.

CONCLUSION

Activating the spinal D2 receptor or blocking the supraspinal D2 receptor produces antinociception. D1 receptor might be not directly involved in the antinociception. l-THP (as a D2 antagonist) as well as spiperone produces antinociception via blocking the supraspinal D2 receptor.

Glutathione conjugates of 2- or 6-substituted 5,8-dimethoxy-1,4-naphthoquinone derivatives: formation and structure

Thirty-four glutathione conjugates of 5,8-dimethoxy-1,4-naphthoquinones (DMNQ) were synthesized and their structure was determined. The yield of GSH conjugate was dependent on size of alkyl group; the longer the size of alkyl group was, the lower was the yield. It was also found that the length of alkyl side chain influenced the chemical shift of quinonoid protons; the quinonoid protons of 2-glutathionyl DMNQ derivatives with R=H to propyl, 6.51-6.59 ppm vs. other ones with R=butyl to heptyl, 6.64-6.68 ppm. This was explained to be due to a folding effect of longer alkyl group. Glutathione (GSH) reacted with DMNQ derivative first to form a 1,4-adduct (2- or 3-glutathionyl-1,4-dihydroxy-5,8-dimethoxynaphthalenes) and then, the adduct was autooxidized to 2- or 3-glutathionyl-DMNQ derivatives. Moreover, GSH reduced DMNQ derivatives to their hydrogenated products. It was suggested that such an organic reaction might play an important role for a study of metabolism or toxicity of DMNQ derivatives in the living cells.

Effect of tetrahydropalmatine analogs on Fos expression induced by formalin-pain

AIM

To study the effect of tetrahydropalmatine (THP) analogs on Fos protein expression induced by formalin-pain and elucidate analgesic mechanism of THP analogs.

METHODS

The pain response to Sprague Dawley rats was induced with formalin injected s.c. into the plantar surface of the right hindpaw. Fos protein expression in brain and spinal cord was investigated with immunohistochemistry. The numbers of Fos-like immunoreactive (FLI) neurons were counted with Leica Q570 image analyzer.

RESULTS

In the groups of THP analogs and D2 antagonist spiperone, FLI neurons induced by intraperitoneal (i.p.) injection of THP analogs and spiperone were mainly located in the striatum and accumbens nucleus, and a few FLI neurons were also in sensorimotor cortex. In the D1 antagonist, D1 agonist, D2 agonist, saline and vehicle groups, FLI neurons were seldom seen in the striatum and accumbens nucleus. Moreover, the Fos protein expression induced by l-THP and spiperone could be prevented by the pre-treatment of the D2 agonist quinpirole but not D1 agonist SKF38393. In the formalin-pain group, FLI neurons were mainly distributed in ascending pain afferent system (APAS) and descending pain modulation system (DPMS). Following i.p. THP analogs, however, the numbers of FLI neurons induced by formalin-pain in the APAS, such as dorsal horn (mainly laminae I, II, IV-VI) were markedly decreased, while the numbers of FLI neurons in the DPMS, such as periaqueductal gray (PAG) and reticular paragigantocellular lateral nucleus (RPLN) were significantly increased.

CONCLUSION

THP analogs enhanced the activity of brainstem DPMS by the blockade of D2 receptors in the striatum and accumbens nucleus, and sequentially inhibited the inputs of peripheral pain afferent message in spinal cord level.

Increased phosphorylation of DARPP-32 by D1 agonistic action of l-stepholidine in the 6-OHDA-lesioned rat striatum

In order to explore the characteristics of l-stepholidine (SPD) activating the postsynaptic D(1) receptors, the effects of SPD on DARPP-32 phosphorylation in vivo with back-phosphorylation assay and on the postsynaptic D(1) receptor densities with radioligand assay were observed in the striatum of 6-OHDA-lesioned rat. The results showed that following subcutaneously administration of 20 or 40 mg/kg SPD for 21 d, (32)P phosphate incorporation into the DARPP-32 protein in the denervated striatum showed a 50% reduction (P<0.01) vs the intact striatum, indicating an increase of DARPP-32 phosphorylation in vivo in the denervated striatum. However,the D(1) receptor B(max) was decreased from 385.0+/-26.1 to 319.7+/-20.1 fmol/mg protein. It is suggested that D(1) agonist action of SPD decreases the D(1) receptor density but increases the phosphorylation of DARPP-32 in the striatum of 6-OHDA-lesioned rat, which may be responsible for the regulation of D(1) receptor signal transduction in brain neurons.

[Antagonistic effect of tetrahydroproberberine homologues on alpha 1-adrenoceptor]

The antagonistic effect of tetrahydroproberberine (THP) homologues on alpha 1-adrenoceptor was studied by combination of radioligand binding assays and measurements of vasoconstriction responses. The results showed that l-tetrahydropalmatine (l-THP), l-stepholidine (l-SPD), THPB-18 and tetrahydroberberine (THB) competitively inhibited the 125I-BE2254 specific binding in rat cerebral cortex with pK1 values of 5.54 +/- 0.36, 5.56 +/- 0.47, 5.75 +/- 0.56 and 6.01 +/- 0.60, respectively, and the Hill efficiency was not significantly different from unity. They inhibited phenylephrine-induced constrictions with pA2 values of 5.48 +/- 0.58, 5.66 +/- 0.54, 5.64 +/- 0.34 and 5.45 +/- 0.76, respectively, and the slopes of Schild plot were not significantly different from unity. The results indicate that the 4 THP homologues are non-subtype selective competitive antagonists for alpha 1-adrenoceptor with similar affinities.

Anthracene-1,4,9,10-tetraone derivatives: synthesis and antitumor activity

A series of 2-alkylated anthracene-1,4,9,10-tetraone (ATO) derivatives were synthesized, and their antitumor action in ICR mice bearing S-180 cells and antiproliferative activity against L1210 cells were evaluated. Overall, the introduction of an alkyl group (C1-C8) at C-2 enhanced the antiproliferative activity. Among 2-(1-hydroxyalkyl)- or 2-(1-acetoxyalkyl)-ATO derivatives, four compounds possessing alkyl chain of an intermediate size (C4-C6) gave T/C values of > 300%. Acetylation at 1'-OH failed to cause an enhancement in the antitumor action, in contrast to a remarkable increase in antiproliferative activity. Although there was no direct relationship between antiproliferative activity and antitumor action, the compounds with lower antiproliferative activity tended to show higher antitumor activity. Further study shows that the antiproliferative activity of ATO derivatives may be explained properly neither by redox cycling nor arylating capacity.

Comparison of (-)-stepholidine and D1 or D2 agonists on unit firing of globus pallidus in 6-hydroxydopamine-lesioned rats

(-)-Stepholidine(SPD), isolated from the Chinese herb Stephania, is demonstrated to be a DA antagonist, but it also shows D1 agonistic action on rotational behavior in unilateral 6-hydroxydopamine (6-OHDA) lesioned rats. The present study further ascertains its D1 agonistic property on firing activity of globus pallidus (GP) in control and 6-OHDA-lesioned rats. In the control rats, the firing activities of the GP neurons elicited by DA agonists (i.v.), such as apomorphine (D1/D2), SKF38393 (D1), and LY171555 (D2), were readily reversed by SPD (4 mg/kg, i.v.); but SPD, per se, induced variable alterations. In the 6-OHDA-lesioned rats, apomorphine, SKF38393 and LY171555 displayed the marked inhibition as well as excitation on the unit firing. The individual firing variations (87.1+/-17.8, 55.1+/-15.7 and 62.1+/-16.7%, respectively) were much larger than those in the control group, and were completely abolished by SPD (2 mg/kg). However, SPD also showed D1 partial agonistic action on the GP neuron firing. Moreover, the pre-blockade of D2 receptors with spiperone (0.5 mg/kg, i.v.), SPD exhibited the D1 agonist action which was reversed by the D1 antagonist SCH23390. These results suggest that SPD has a dual action on the GP neuron firing in the 6-OHDA-lesioned rats, i.e., antagonist to D2 DA receptors and partial agonist to D1 receptors.

D1/D2 dopamine receptor interaction in membrane abolished by 6-hydroxydopamine lesion

D1/D2 interaction in rat striatum was investigated by examining the effect of the D2 antagonist spiperone on the binding of [3H]SCH23390 to D1 dopamine (DA) receptors. In the presence of endogenous DA, spiperone blocked D2 receptors, then caused the increase of the binding of [3H]SCH23390 in rat striatal homogenate. After the 6-hydroxydopamine (6-OHDA) lesion, the increase was not found even if in the addition of exogenous DA. The results suggest that the D2 antagonist can modify the interaction between endogenous DA and D1 receptors labeled with [3H]SCH23390, while 6-OHDA lesion may change the state of D1/D2 interaction operating at the receptor level.

Involvement of dopamine D1 and D2 receptors in Fos immunoreactivity induced by stepholidine in both intact and denervated striatum of lesioned rats

Stepholidine (SPD), a natural product, has been demonstrated in previous studies as a D1 agonist and D2 antagonist. In this work SPD-induced Fos immunoreactivity was examined. In the normal rats, Fos was induced in the striatum by SPD (1-20 mg/kg, i.p.) dose-dependently. The distribution of Fos-positive cells induced by SPD showed a rostral-caudal decline, matching the distribution of D2 dopamine receptors. The Fos-positive cells were mainly found in striatal neurons retrogradely labeled with horseradish peroxidase (HRP) from GP but not from SN, and could be abolished by the pretreatment of a D2 agonist LY171555 (2 mg/kg, i.p.), suggesting that the Fos expression in normal rats was due to the D2 antagonistic action of SPD. In the unilateral 6-hydroxydopamine-lesioned rats, SPD (4 mg/kg, i.p.) induced Fos expression in intact and denervated side of the striatum with different characteristics. Similar to that of normal rats, the Fos expression in intact side possessed the rostral-caudal gradient and could be abolished by the pretreatment of LY171555. However, in the denervated side, the Fos positive cells were widely distributed, and mainly found in striatal neurons retrogradely labeled from SN but not from GP. Furthermore, this expression was prevented by the pretreatment of SCH23390 (0.2 mg/kg, i.p.) but not LY171555, suggesting that the Fos expression in denervated side was due to the D1 agonistic action of SPD. Therefore, we concluded that the Fos expression induced by SPD in intact and denervated striatum was mediated via D2 and D1 receptor respectively, supporting the previous standpoint that SPD possesses the dual action, i.e antagonist to D2 and agonist to D1 receptors. Furthermore, it is suggested that the contralateral turning behavior induced by SPD may result from the D1-mediated excitation of striatonigral neurons of the denervated side of the lesioned rats.

2-(1-Oxyalkyl)-1,4-dioxy-9,10-anthraquinones: synthesis and evaluation of antitumor activity

Fourty eight derivatives of 2-(1-oxyalkyl)-1,4-dioxy-9,10-anthraquinone were synthesized, and their antitumor activity was evaluated. On the whole, 2-(1-hydroxyalkyl)-1,4-dihydroxy-9,10-anthraquinones (DHAQ = 1,4-dihydroxy-9,10-anthraquinone) showed stronger cytotoxic activity against L1210 cells than 2-(1-hydroxyalkyl)-1,4-dimethoxy-9,10-anthraquinones(DMAQ = 1,4-dimethoxy-9,10-anthraquinone), implying that free hydroxy groups at C-1 and C-4 of the anthraquinone structure are necessary for the cytotoxic activity. The bioactivity of 2-(1-hydroxyalkyl)-DHAQ derivatives differed according to the size of alkyl group at C-1; while the elongation of alkyl group over 7 carbon atoms failed to enhance the bioactivity, the derivatives possessing alkyl moiety of 1-6 carbon atoms showed an increase in the cytotoxicity and the antitumor activity in Sarcoma-180; 2-hydroxymethyl-DHAQ (ED50, 15 micrograms/ml; T/C, 125%), 2-(1-hydroxyethyl)-DHAQ(1.9 micrograms/ml; 139.2%), 2-(1-hydroxypropyl)-DHAQ (7.2 micrograms/ml; 135.1%), 2-(1-hydroxybutyl)-DHAQ (10.2 micrograms/ml; 125.3%), 2-(1-hydroxypentyl)-DHAQ (23.7 micrograms/ml; 110.1%), and 2-(1-hydroxyhexyl)-DHAQ (58 micrograms/ml; 108%). Next, 2-(1-Hydroxyalkyl)-DHAQ derivatives were acetylated to produce 2-(1-acetoxyalkyl)-DHAQ analogues. Although the acetylation somewhat enhanced the cytotoxicity, but not the antitumor action. In addition, the presence of phenyl group at C-1' enhanced the cytotoxicity and the T/C value, compared to alkyl groups of same size; 2-(1-hydroxy-1-phenyl)-DHAQ (ED50, 5.6 micrograms/ml; T/C, 137%).

Enhancement of (-)-stepholidine on protein phosphorylation of a dopamine- and cAMP-regulated phosphoprotein in denervated striatum of oxidopamine-lesioned rats

AIM

To study effects of (-)-stepholidine (SPD) on the phosphorylation of a dopamine- and cAMP-regulated phosphoprotein (DARPP-32) in the striatum of oxidopamine-lesioned rats.

METHODS

The amount of dephospho-DARPP-32 was measured by a back-phosphorylation assay.

RESULTS

In the striatum of control rats, SPD per se had no effect on the phosphorylation of DARPP-32, but it antagonized the decrease by 28% of dephospho-DARPP-32 induced by the D1 agonist SK&F-38393. In the denervated striatum of oxidopamine-lesioned rats, SPD decreased the amount of dephospho-DARPP-32 by 44%. The effect of SPD was completely counteracted by the concomitant administration of the D1 antagonist Sch-23390.

CONCLUSION

SPD exhibits D1 agonistic action on DARPP-32 phosphorylation in the denervated striatum of oxidopamine-lesioned rats, but it acts as a D1 antagonist in normal striatum.

Tetrahydroberberine blocks membrane K+ channels underlying its inhibition of intracellular message-mediated outward currents in acutely dissociated CA1 neurons from rat hippocampus

In the patch-clamp perforated whole-cell recording mode, tetrahydroberberine (THB), a novel dopamine (DA) receptor antagonist, inhibits not only DA-induced outward K+ currents, but also acetylcholine-, caffeine- or strychnine-induced outward current. However, THB does not affect either GABA- or glycine-induced Cl- currents, or non-NMDA receptor agonist-induced cation currents. As expected for a K+ channel blocker, THB evokes a downward current deflection accompanied by a decrease of conductance. It is concluded that the direct blockade of membrane K+ channels by THB underlies its inhibition of intracellular message-mediated outward currents.

Involvement of receptor reserve in D1 agonistic action of (-)-stepholidine in lesioned rats

(-)-Stepholidine (SPD) is a natural product. Previous studies had demonstrated that SPD displayed D1 agonism in unilaterally 6-hydroxydopamine (6-OHDA)-lesioned rats and D1 antagonism in reserpinized rats and normal rats. The aim of the present study was to explain this peculiar pharmacological action based on behavioral and biochemical experiments. In the unilaterally 6-OHDA-lesioned rats, SPD (4 mg/kg, s.c.) induced contralateral rotation as did apomorphine (APO), but the rotation response to SPD was 60% lower than that to APO (0.5 mg/kg, i.p.). Coadministration with APO (0.5 mg/kg, i.p.) and SPD (0.5 to 10 mg/kg, s.c.) produced a biphasic action curve. At low doses (0.5 or 1 mg/kg), SPD potentiated APO action; at high doses (4 or 10 mg/kg), however, SPD suppressed APO. In striatal homogenate of the unilaterally lesioned rats, SPD stimulated cyclic AMP (cAMP) formation and produced a maximal response comparable to that of dopamine (DA) in the denervated striatum, but 70% lower than that of DA in the intact striatum. Coadministration of 10 microM DA with various concentrations of SPD yielded different results, with a biphasic response in the intact side and a synergistic effect in the denervated side. Furthermore, based on the determination of receptor-mediated cAMP formation, the D1 receptor reserve was analyzed in both denervated and intact striatum by using the DA receptor inactivator N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ). The results showed that following EEDQ administration, the receptor density [revealed by [3H]R(+)-7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-be nzazepine ([3H]SCH-23390) binding] and the agonist-stimulated adenylate cyclase (AC) activity (revealed by cAMP formation) were reduced concurrently. In the intact striatum, the reduction in SPD-stimulated AC activity paralleled the receptor loss, indicating the absence of receptor reserve, while in the denervated striatum the reduction in AC activity was less than the receptor loss, indicating a significant level of receptor reserve (estimated 16.4%). By comparison, receptor reserve for DA was 45.7 and 25.3% in the denervated and intact striatum, respectively, representing an 80% increase of receptor reserve. In conclusion, SPD is a D1 partial agonist, and receptor reserve permits SPD to display its D1 agonistic action in the unilaterally 6-OHDA-lesioned rats.

GTP regulation of (-)-stepholidine binding to R(H) of D1 dopamine receptors in calf striatum

(-)-Stepholidine (SPD) exhibits antagonist effects on normosensitive dopamine (DA) receptors, but it has an agonist action on rotation in unilaterally 6-hydroxydopamine (6-OHDA)-lesioned rats. The present work endeavors to further elucidate the mechanism of its agonist action on D1 receptors. [3H]R(+)-7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-be nzazepine ([3H]SCH-23390) and [3H]spiperone were used, respectively, as radioligands in D1 and D2 DA receptor binding assays in calf striatal membranes. Experimental data were analyzed by a non-linear regression computer program, GraphPAD InPlot 3.15. The competition curves were fitted first by a single-site equation and then by a two-site equation. The results showed that both apomorphine (APO) and SPD competitively inhibited [3H]SCH-23390 binding. Their competition curves fitted best to the two-site equation (P < 0.05) with a high-affinity site (R(H)) and a low-affinity site (R(L)) to DA receptors. The K(H) and K(L) values (nM) were 2.7 +/- 0.45 and 378 +/- 62 for APO, and 3.9 +/- 2.2 and 126 +/- 25 for SPD, respectively. In contrast, the competition curve of SCH-23390, a selective D1 DA receptor antagonist, fitted best to a single-site model with a Ki value of 1.7 +/- 0.5 nM. The R(H) of APO or SPD could be decreased by the addition of 450 microM GTP. In the [3H]spiperone binding test, the APO curve was modeled best by the two-site equation, while the SPD curve fitted best to a single-site model. In the rotational behavior test, APO induced 441 +/- 20 turns/30 min in the 6-OHDA-lesioned rats, and SPD induced 310 +/- 42 turns/30 min, while SCH-23390 antagonized the SPD-induced rotation but did not induce rotational behavior. These results suggest that SPD possesses agonist actions on D1 but antagonist effects on D2 DA receptors.

Characteristics of tetrahydroprotoberberines on dopamine D1 and D2 receptors in calf striatum

AIM

To study the characteristics of tetrahydroprotoberberines (THPB) on dopamine D1 and D2 receptors and elucidate their structure-activity relationship.

METHODS

Radioligand assay in vitro with a two-site model program analysis.

RESULTS

Four THPB with two hydorxyl groups on C2 and C9 or C2 and C10 exhibited RH and RL two binding sites to D1 receptors and guanosine triphosphate regulated the RH binding site of SPD and THPB-132A in competition assay, while eleven THPB including nonhydroxy-THPB, monohydroxy-THPB, and THPB with two hydroxyl groups attaching to C3 and C10 showed one binding site to D1 receptors under the same conditions. However, the tested eleven THPB all manifested one binding site to D2 receptors in competition assay, and the 2-hydroxy-THPB had the most potent affinity for D2 receptors.

CONCLUSION

Dihydroxy-THPB with two hydroxyl groups attaching to C2 and C9 or C2 and C10 possess the intrinsic activity of agonist to D1 receptors, while the other THPB do not. The tested eleven THPB all are the antagonists of D2 receptors.

Effects of tetrahydroprotoberberines on dopamine D2 receptors in ventral tegmental area of rat

AIM

To compare the actions of tetrahydroprotoberberines (THPB) on dopamine (DA) D2 receptors in the ventral tegmental area (VTA) of rat.

METHODS

Extracellular single unit recording technique was used in i.v. gallamine-paralyzed rats.

RESULTS

Eleven THPB analogs tested completely attenuated the apomorphine (Apo, 20 micrograms.kg-1)-induced inhibition on VTA DA cell firing activity. The OH group on C2 at THPB was linked with the reversal of Apo-induced inhibition. Their reversal potencies (ED50, microgram.kg-1) for D2 receptors were: THPB-143 (5.6) > SPD (8.5) > Iso (17.0) > THP (33) > THB (48) > THPB-18 (66) > THPB-1 (179) > THPB-19 (408) > THPB-126 (510) > THPB-104 (1019) > THPB-10 (4815).

CONCLUSION

Among these 11 THPB, the 2-hydroxyl-THPB (THPB-143) showed the strongest antagonistic action on D2 receptors.

Tetrahydroberberine inhibits acetylcholine-induced K+ current in acutely dissociated rat hippocampal CA1 pyramidal neurons

The effects of a novel chemical type of dopamine receptor antagonist, the tetrahydroprotoberberine analogs (THPBs), on acetylcholine (ACh)-induced current were studied in freshly dissociated pyramidal neurons from rat hippocampal CA1 area using the nystatin perforated patch-clamp recording technique. Under voltage clamp conditions, the ACh-induced outward current (IACh) is sensitive to the muscarinic receptor antagonist, atropine and the K+ channel blocker, TEA. The reversal potential of IACh (-84.1 +/- 0.8 mV) is close to the K+ equilibrium potential, indicating that the IACh is mediated by a muscarinic receptor, and is carried mainly by K+. Tetrahydroberberine (THB) markedly reduced the IACh while its chemical analogs, l-stepholidine (l-SPD) or l-tetrahydropalmatine (l-THP), had little effect on the IACh. The half-maximal inhibitory concentration (IC50) of THB was 1.3 x 10(-5) M for a 10(-5) M ACh-induced IACh. THB suppressed the maximum of the ACh concentration-response curve without shifting the Hill coefficient, indicating a non-competitive inhibition. It is concluded that THB non-competitively inhibits the ACh-induced K+ current in a concentration-dependent manner, and that this inhibitory effect provides further evidence that THB plays its pharmacological roles in the central nervous system by effects other than through blockade of dopamine receptors.

(-)-Stepholidine enhances K+ depolarization-induced activation of synaptosomal tyrosine 3-monooxygenase from rat striatum

AIM

To study the mechanism of K+ depolarization-induced activation of synaptosomal tyrosine 3-monooxygenase (TM) in rat striatum and the effect of (-)-stepholidine (SPD) on this activation.

METHODS

The TM was assayed for DOPA by HPLC-ECD; the activities of Ca2+/calmodulin (CaM)-dependent protein kinase (PK II) and Ca2+/phosphoinositide-dependent protein kinase (PKC) were assayed using histidine as substrate.

RESULTS

The incubation of striatal synaptosomes in K(+)-riched (60 mmol.L-1) medium resulted in a marked activation of TM. PKC inhibitor polymyxin B (PMB) completely blocked the activation of K+ 60 mmol.L-1 on TM. Selective D2 receptor agonist quinpirole (QP), Ca2+ removal from incubation medium and CaM antagonist W7 failed to affect the activation. However, SPD enhanced the activation of K+ 60 mmol.L-1 on TM. Meanwhile, the incubation in K+ 60 mmol.L-1 also activated PKC. Neither QP nor SPD affected K+ depolarization-induced activation of PKC.

CONCLUSION

The activation of K+ depolarization on synaptosomal TM is enhanced by SPD and this activation is mediated by PKC rather than by PK II.

Dual actions of (-)-stepholidine on the dopamine receptor-mediated adenylate cyclase activity in rat corpus striatum

(-)-Stepholidine (SPD) is an antagonist of normosensitive dopamine (DA) receptors, but it exhibits D1 agonistic action on rotational behaviour in rats with unilateral 6-hydroxydopamine (6-OHDA) lesions of the substantia nigra pars compacta (SNC). In the present study, agonistic and antagonistic effects of SPD on the DA receptor-mediated synaptosomal adenylate cyclase (AC) activity in rat striatum were investigated. After blockade of D2 receptors, SPD augmented AC activity dose-dependently. The EC50 value was 41.1 +/- 8.6 micromol/L. At the concentration of 10 micromol/L, SPD increased cAMP formation from a basal level (50.8 +/- 10.3 pmol/mg protein/min) to 133.7 +/- 31.8 pmol/mg protein/min. The SPD-induced stimulation of AC activity was almost completely reversed by 10 micromol/L Sch23390. These results indicate that SPD possesses an agonistic action on the D1 receptor. Forskolin-stimulated adenylate cyclase (FSAC) activity was used as a model to elucidate the effect of SPD on D2 receptors. The results indicate that DA inhibited FSAC activity dose-dependently, while SPD partially restored FSAC activity. Taken together, these results support the conclusion that SPD has dual actions on DA receptors that mediate AC activity, i.e., an agonistic action on D1 receptors and an antagonistic action on D2 receptors.

Chronic treatment with (-)-stepholidine alters density and turnover of D1 and D2 receptors in striatum

AIM

To study the effects of chronic administration of SPD on the density and turnover of striatal D1 and D2 dopamine (DA) receptors.

METHODS

Receptor density was monitored by radio-receptor binding assay. The receptor recovery and turnover were studied after irreversible inactivation by N-ethoxycarbonyl-2-ethoxy-1, 2-dihydro-quinoline (EEDQ).

RESULTS

Chronic SPD treatment (sc, 20 mg.kg-1.d-1 x 21 d) upregulated both striatal D1 and D2 receptor density. As compared to vehicle-treated rats, SPD increased D1 and D2 receptors by 41.5% and 43.7%, respectively SPD also altered the turnover of both D1 and D2 receptors. The degradation rate constant (k = 0.0082.h-1) and the synthesis rate (r = 2.65 pmol.h-1/g protein) of D2 receptors in SPD-treated rats were significantly increased vs vehicle-treated rats (k = 0.0049.h-1; r = 1.10 pmol.h-1/g protein). The degradation rate constant (k = 0.0059.h-1) and the synthesis rate (r = 3.1 pmol.h-1/g protein) of D1 receptors was also increased in SPD-treated rats vs vehicle-treated rats (k = 0.0048.h-1; r = 1.8 pmol.h-1/g protein), but the alteration of degradation rate constant missed significance (P > 0.05). As a result, receptor recovery following EEDQ was accelerated. The half time for D1 and D2 receptors recovery in SPD group were 117.5 h and 84.5 h, respectively, shorter than 144.4 h and 141.4 h in vehicle-treated rats.

CONCLUSION

Chronic SPD treatment upregulated D1 and D2 receptors, and accelerated DA receptor turnover and recovery mainly by increasing receptor synthesis.

D1 dopamine receptor stimulation inhibits firing activity of midbrain dopamine neurons in reserpine treated rats: an effect eliminated after hemitransection of diencephalon

It has been reported that systemic administration of the D1 dopamine (DA) receptor agonist SKF 38393 inhibits the firing rate of substantia nigra pars compacta (SNC, A9) DA neurons after repeated reserpine treatment in locally anesthetized rats, although SKF 38393 induces little effect on the firing of midbrain DA neurons in normal rats. The present study found that local pressure microejection of SKF 38393 (10(-2) M, 20-100 nl) to SNC or substantia nigra pars reticulata (SNR) failed to influence the firing of SNC DA neurons in reserpinized rats (reserpine 1 mg/kg x 6 days, s.c.); subsequent intravenous (i.v.) injection of SKF 38393 (4 mg/kg), however, inhibited their firing and the inhibition was reversed by the D1 receptor antagonist SCH 23390. Similarly, systemic administration of SKF 38393 (4 mg/kg, i.v.) inhibited the firing of ventral tegmental area (VTA, A10) DA cells in reserpinized rats, while local microejection of SKF 38393 (10(-2) M, 30-60 nl) did not affect their firing. Furthermore, the inhibitory effect of systemic SKF 38393 on firing rate of either SNC or VTA DA neurons in reserpinized rats was eliminated after hemitransection of diencephalon. These results suggest that repeated reserpine treatment renders midbrain DA neurons responsive to D1 receptor stimulation and that D1 receptor agonist-induced inhibition of midbrain DA cell firing in reserpinized rats may require the involvement of long-loop feedback pathways.

Effect of (-)-stepholidine on serum prolactin level of female rats

AIM

To study the effect of (-)-stepholidine (SPD) on serum prolactin (PRL) level and elucidate its pharmacological action on dopamine D2 receptors.

METHOD

After i.p. administration of dopamine receptor agonist, antagonist, or SPD, the serum PRL levels were determined by radioimmunoassay.

RESULTS

SPD (24 mg.kg-1, i.p.) caused a rapid rise in serum PRL level, lasting more than 1 h. SPD 0.2-40 mg.kg-1 raised serum PRL level in a dose-dependent manner with ED50 of 3.7 mg.kg-1 (95% confidence limits, 2.6-4.3 mg.kg-1) and PRL maximal level of 448 +/- 64 micrograms.L-1. Pergolide 2 mg.kg-1 i.p. caused a decrease (P < 0.01 vs saline) of PRL level, which was partially attenuated by SPD of 5 mg.kg-1 and completely abolished by 10 mg.kg-1.

CONCLUSION

SPD is a dopamine D2 receptor antagonist.

[Antagonism of l-stepholidine against bromocriptine-inhibition on prolactin level in lactational rats]

AIM

To study the antagonism of l-stepholidine (SPD) against bromocriptine (Bro)-inhibition on prolactin (PRL) level.

METHODS

Bro (0.5 mg.kg-1.d-1, s.c.) reduced the PRL and caused a dysplasia of mammary gland in lactational rats. The weight growing of newborn rats was retarded. The PRL of the lactational rats was assessed by immunoradiometric assay (IRMA); the weight of newborn rats and development of mammary glands in lactational rats were also examined. Antagonism of SPD was evaluated.

RESULTS

SPD (30 & 100 mg.kg-1.d-1, i.p.) obviously antagonized the Bro that induced lowering the PRL level in lactational rats, the PRL was 11 +/- 4 & 23 +/- 6 micrograms.L-1 (NS 7 +/- 2) respectively on d 15 of postpartum and the development of mammary gland in lactational rats was normal. The newborn rats grew rapidly in 11-15 d.

CONCLUSION

SPD possessed an antagonism with Bro inhibition on D2 receptors located in the pituitary gland, and was an antagonist of dopamine D2 receptors.

(-)-Stepholidine acts as a D1 partial agonist on firing activity of substantia nigra pars reticulata neurons in 6-hydroxydopamine-lesioned rats

(-)-Stepholidine (SPD), a novel dopamine (DA) D1 and/or D2 receptor antagonist in normosensitive animals, shows agonistic effects on D1 receptors in rotational behavior of 6-hydroxydopamine (6-OHDA)-lesioned rats. To further characterize the pharmacological properties of SPD, we investigated the effects of SPD on firing activity of substantia nigra pars reticulata (SNR) neurons in different sensitive models. In control rats, the selective D1 agonist SKF38393 (4 mg/kg, i.v.) induced inconsistent changes (i.e. increase, decrease or no change) in firing of SNR neurons. These effects were completely antagonized by SPD (i.v.), regardless of the changes induced by SKF38393. SPD (4 mg/kg), per se, increased firing by 30.9 +/- 14.4%. In reserpinized rats, SKF38393 also induced SPD-reversible inconsistent changes as in control rats. Nevertheless, SPD per se produced no alteration in firing of SNR neurons. In 6-OHDA-lesioned rats, 5/6 SNR neurons were inhibited by SKF38393. The inhibition was completely abolished by Sch23390, a selective D1 antagonist (0.5-2 mg/kg), but partially reversed by SPD (1-16 mg/kg). Moreover, SPD (4 mg/kg) itself caused SNR increased or decreased neuron firing, and these effects were completely reversed by Sch23390 (0.5-2 mg/kg) in 8/12 neurons recorded. These results suggest that SPD acts as a partial agonist to D1 receptors in 6-OHDA-lesioned rats, but as an antagonist to D1 receptors in normal and reserpinized rats.